NATIONAL INSTITUTES OF HEALTH

MIT chemists have developed antibody-bottlebrush conjugates (ABCs) that can deliver hundreds of drug molecules per antibody, compared to the maximum of eight in current FDA-approved ADCs.

LinusBio published research in The Lancet's eBioMedicine demonstrating a novel hair-based biomarker for ALS detection using copper-related elemental patterns.

Stanford University has been awarded a double-digit million dollar NIH grant to conduct a Phase II trial of Tiprelestat for pulmonary arterial hypertension, with patient enrollment expected to begin in mid-2026.

BridgeBio's oral calcilytic encaleret demonstrated parathyroid hormone-independent normalization of blood and urine calcium in a Phase 2 proof-of-concept study for post-surgical hypoparathyroidism.

Novaremed has completed the last patient visit for 127 participants in its NIH-funded Phase 2b trial evaluating nispomeben for chronic pain associated with diabetic peripheral neuropathy.

Circurna and GATC Health announced a strategic partnership to apply advanced AI technology for optimizing circular RNA therapeutics development.

Lighthouse Pharmaceuticals received a $49.2 million grant from the National Institute on Aging to advance Phase 2 trials of LHP588, targeting Porphyromonas gingivalis infections in Alzheimer's disease patients.

The U.S. Senate Appropriations Committee passed bipartisan legislation encouraging the FDA to develop alternative clinical trial endpoints for Alcohol Use Disorder beyond abstinence, including reduced cravings and decreased disorder severity.

The Wistar Institute received a five-year, $17 million NIH grant to launch the iCure Consortium, developing individualized cure regimens for HIV through personalized medicine approaches.

Capricor Therapeutics has dosed the first subjects in a Phase 1 clinical trial of its StealthX exosome-based vaccine, marking the first-in-human evaluation of this novel platform.